LP-APHE is a type of selective apheresis by which atherogenic lipoproteins (such as LDL and Lp(a)) are efficiently removed while most other proteins (including the atheroprotective HDL) are not. This is in contrast to therapeutic plasma exchange (TPE) where all plasma proteins are lost with the removed plasma, and a replacement fluid is required.
Conditions treated with LP-AHRE include:
- Hyperlipoproteinemias such as Familial Hypercholesterolemia (FH)
- Elevated LP (a)
- High Risk lipoproteinemias where patients have experienced cardiovascular and/or cerebrovascular events
- Certain sub-populations of patients with focal segmental glomeruloscherosos (FSGS)
For more information on LP-AHRE contact our Clinical Services Team at 914-784-4602.
Lipoprotein Apheresis Resources
Effectiveness of lipoprotein apheresis
- Beneficial effect of LDL-apheresis in refractory nephrotic syndrome
Muso E. Clin Exp Nephrol. 2014 Apr;18(2):286-90. doi: 10.1007/s10157-013-0930-5. Epub 2014 Feb 18. Review.
Lipoprotein Apheresis Webinar
Presented by Bruce Sachais, MD, PhD
Executive Medical Director, NYBC
Fellowship Director, NYBC
Immediate Past President, ASFA
Vice President Americas, ISFA